Oric Pharmaceuticals, Inc. Common StockORIC
Recorded
Oric Pharmaceuticals, Inc. Common Stock 12th Annual Cantor Fitzgerald Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0Duration30 min
Key takeaways
- ORIC is focused on two late-stage clinical programs: Rinsey Medistat, a PRC2 inhibitor for castration-resistant prostate cancer (CRPC), and Enosertinib, a brain-penetrant lung cancer compound targeting EGFR exon 20 and atypical mutations in non-small cell lung cancer.
- Rinsey Medistat has entered its first phase three study, HIMLAS1, and Enosertinib will present data at ESMO with plans to start a phase three study next year.
- Pfizer's MEPRO1 phase three trial readout is expected in Q4, which ORIC views as a positive signal for the class and their own program.
- ORIC believes the synergy of PRC2 inhibitors with androgen receptor (AR) inhibitors is supported by multiple datasets, and they remain confident in their phase three trial despite various potential MEPRO1 outcomes.
- The HIMLAS1 study design is similar to MEPRO1 but includes a cap on control arm treatment distribution and excludes ECOG status 2 patients.
- ORIC expects a clinically meaningful progression-free survival (PFS) hazard ratio around 0.66, with a control arm median PFS of approximately 6.75 months and treatment arm over 10 months.
- Rinsey Medistat has pharmacokinetic advantages over Pfizer's MEPRO Medistat, including a longer half-life and no drug-drug interaction with darolutamide, potentially allowing better safety and efficacy.
- The addressable market for HIMLAS1's CRPC population is about 17,000 patients in the US, representing a $3.5 billion market; globally, the market is about $7 billion.
- Enosertinib targets a US patient population of about 6,000 with a total addressable market of approximately $2.5 billion for atypical EGFR mutations.
- ORIC plans to explore monotherapy and combination therapies for Enosertinib, including with chemotherapy and Embiventimab, focusing on CNS activity due to high rates of brain metastases in the patient population.
- ORIC ended Q2 with $388 million in cash and investments, providing runway into the second half of 2028, covering HIMLAS1 and planned phase three studies for Enosertinib.
- Management emphasized a pragmatic, data-driven approach to development and potential partnerships to maximize value for both assets.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring